Curi RMB Capital LLC Sells 29,662 Shares of Catalent, Inc. (NYSE:CTLT)

Curi RMB Capital LLC lowered its position in shares of Catalent, Inc. (NYSE:CTLT) by 23.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 96,590 shares of the company’s stock after selling 29,662 shares during the quarter. Curi RMB Capital LLC’s holdings in Catalent were worth $5,850,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of CTLT. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Catalent during the 2nd quarter valued at about $42,000. Sentry Investment Management LLC bought a new position in Catalent during the third quarter valued at approximately $53,000. Longfellow Investment Management Co. LLC raised its stake in shares of Catalent by 45.7% during the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after acquiring an additional 305 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Catalent by 25.9% during the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares in the last quarter. Finally, Intact Investment Management Inc. bought a new stake in shares of Catalent in the 3rd quarter worth approximately $73,000.

Catalent Stock Down 0.3 %

NYSE CTLT opened at $58.95 on Friday. Catalent, Inc. has a 1 year low of $36.00 and a 1 year high of $61.20. The stock has a market capitalization of $10.70 billion, a PE ratio of -26.07, a PEG ratio of 2.36 and a beta of 1.16. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The business’s 50-day moving average is $59.89 and its 200 day moving average is $58.16.

Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the business posted ($0.10) EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. Sell-side analysts forecast that Catalent, Inc. will post 0.84 earnings per share for the current year.

Analyst Ratings Changes

CTLT has been the topic of several recent research reports. Robert W. Baird reaffirmed a “neutral” rating and set a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. StockNews.com upgraded Catalent from a “sell” rating to a “hold” rating in a report on Thursday. Baird R W cut Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Finally, William Blair reaffirmed a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Nine analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, Catalent presently has an average rating of “Hold” and an average price target of $59.83.

Insider Activity at Catalent

In related news, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This represents a 5.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the completion of the transaction, the director now owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock worth $305,931 over the last quarter. Corporate insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.